Nipple Discharge: Causes, When It Signals Cancer, and What to Do

Nipple discharge is one of the most common reasons women seek evaluation at a breast clinic — and one of the most misunderstood. Most nipple discharge is benign. The most frequent causes include intraductal papilloma, duct ectasia, and fibrocystic breast change, none of which are cancer. Yet the question of nipple discharge cancer is a real one: in women presenting with nipple discharge as their only symptom, cancer is identified in approximately 5 to 12% of cases. When discharge is bloody and accompanied by a palpable mass, that risk rises to as high as 25 to 30%.

What this means in practice is that nipple discharge cannot be dismissed — and it cannot be assumed to be cancer. The characteristics of the discharge matter enormously: whether it is coming from one breast or both, whether it occurs spontaneously or only when squeezed, and what color it is. These features help clinicians determine how urgently evaluation is needed and which diagnostic steps are appropriate.

This guide explains every aspect of nipple discharge: what causes it, which features are most and least concerning, how Paget’s disease of the nipple differs from a rash, how the diagnostic workup proceeds step by step, and when you need to act quickly.

3–5% of breast outpatient visits involve nipple discharge — one of the most common breast symptoms

5–12% of isolated discharge cases (no mass) are ultimately found to be cancer

~25–30% cancer probability when bloody discharge accompanies a palpable breast mass

35–48% of pathological discharge cases caused by intraductal papilloma — the most common cause

Types of Nipple Discharge — What the Color and Pattern Mean

Not all nipple discharge is clinically equal. The most important factors in determining whether discharge is likely to be pathological are: laterality (one breast or both), whether it is spontaneous or expressible only, and what color it is.

Unilateral vs. bilateral: Discharge arising from a single breast — particularly from a single duct opening — is more clinically significant. Bilateral discharge is almost universally benign, most often representing galactorrhea. Unilateral discharge from one duct warrants imaging and evaluation.

Spontaneous vs. expressible: Spontaneous discharge occurs without any pressure applied — appearing on clothing or bedding. This is more clinically significant than expressible discharge, which can only be obtained by squeezing. Expressible discharge from multiple duct openings in both breasts is almost always benign.

Bloody or blood-tinged

Most concerning. Associated with intraductal papilloma or — less commonly — DCIS or invasive cancer. Prompt evaluation required regardless of other features.

Clear or watery

Less alarming in appearance but can be associated with DCIS. A hemoccult test checks for occult blood — a positive result significantly increases concern. Warrants evaluation.

Serous (pale yellow)

Most often fibrocystic change or intraductal papilloma. Still warrants evaluation if unilateral from a single duct — papillomas can occasionally harbor atypia or adjacent DCIS.

Green or brown, thick

Hallmark of mammary duct ectasia — a benign condition involving dilated inflamed ducts. Typically bilateral, expressible, from multiple duct openings. Almost always benign.

Milky / white (galactorrhea)

Benign by definition. Caused by elevated prolactin, not breast pathology. Almost always bilateral and expressible. Workup focuses on identifying the prolactin cause, not the breast.

Common Benign Causes of Nipple Discharge

Understanding the benign causes of nipple discharge provides context for what most women presenting with this symptom will ultimately be found to have.

Intraductal Papilloma Discharge: unilateral, spontaneous, bloody or serous The most common cause of pathological discharge (35–48% of cases). A small benign tumor grows within a lactiferous duct, most often just beneath the nipple. Solitary central papillomas carry ~1–3% malignancy risk; multiple peripheral papillomas carry ~10–15% risk of concurrent atypia. Surgical duct excision is standard treatment.

Mammary Duct Ectasia Discharge: thick, green/brown, bilateral, expressible Benign dilation and inflammation of the large subareolar ducts. Common in perimenopausal and postmenopausal women. Can cause nipple retraction due to periductal fibrosis — imaging distinguishes ectasia-related retraction from cancer. Managed conservatively; duct excision if persistent.

Galactorrhea Discharge: milky, white, bilateral, expressible Caused by elevated prolactin from medications (antipsychotics, SSRIs, metoclopramide), prolactinoma, hypothyroidism, or idiopathic hyperprolactinemia. Virtually never cancer. Workup: prolactin level + TSH; pituitary MRI if prolactin >100 ng/mL.

Fibrocystic Change Discharge: serous or cloudy, bilateral, cyclical The most common benign breast condition in premenopausal women. Discharge typically fluctuates with the menstrual cycle — more pronounced premenstrually, lessening after the period. Bilateral and expressible. Imaging confirms no structural cause.

Periductal Mastitis Discharge: purulent or mixed; subareolar tenderness Subareolar infection unrelated to breastfeeding. Strongly associated with smoking. Can cause recurring abscess formation near the nipple and nipple retraction. Managed with antibiotics and drainage; may require surgical duct excision for recurring cases.

When Nipple Discharge May Signal Cancer

Most nipple discharge is benign. But specific combinations of features — in the absence of a physiological explanation like galactorrhea — require investigation to exclude malignancy. The following features are associated with higher likelihood of pathological discharge.

nipple discharge cancer warning signs evaluation — Unilateral, spontaneous, bloody or clear nipple discharge — especially in a postmenopausal woman or when accompanied by a palpable breast mass — requires prompt clinical evaluation. Cancer is identified in approximately 5 to 12% of women presenting with nipple discharge alone, and in up to 25 to 30% when discharge accompanies a mass.

Unilateral, single duct The most reliable indicator of a structural cause in the breast. Discharge from one duct opening in one breast is significantly more concerning than bilateral multi-duct discharge.

Spontaneous discharge Discharge occurring without squeezing — staining clothing or bedding on its own — is more clinically significant than discharge obtained only by manual expression.

Bloody or hemoccult-positive Bloody discharge requires prompt evaluation. Clear discharge testing positive for occult blood carries similar concern. Both are strongly associated with papilloma or, less commonly, DCIS.

Associated palpable mass The combination of nipple discharge and a new breast mass raises the cancer probability to approximately 25–30%. This combination warrants the most urgent evaluation.

New onset postmenopause New nipple discharge after menopause is unusual and warrants explanation. Most postmenopausal cases with pathological discharge will be found to have papilloma, ectasia, or malignancy.

Nipple skin changes Redness, scaling, crusting, or ulceration of the nipple or areola — especially if unilateral — are hallmark signs of Paget’s disease, a malignancy with underlying DCIS or invasive cancer.

When to seek evaluation this week: Any new, unilateral, spontaneous, bloody or clear nipple discharge should be evaluated within one week. Do not wait for a scheduled mammogram — contact your primary care provider or gynecologist directly. If the discharge accompanies a new breast lump, skin dimpling, or nipple skin changes, seek evaluation within 2–3 days.

Cancer Types Associated with Nipple Discharge

Ductal carcinoma in situ (DCIS) is the cancer most commonly presenting as nipple discharge. DCIS is a pre-invasive cancer confined to the milk ducts that has not yet broken through to surrounding tissue. It can cause unilateral, spontaneous, bloody or serous discharge — often without a palpable lump at first presentation. This is why nipple discharge is taken seriously: DCIS can be diagnosed and treated at this early, curable stage, before it progresses to invasive disease.

Invasive ductal carcinoma less commonly presents as nipple discharge alone; it more typically presents as a palpable mass, with discharge as a secondary finding. When a mass accompanies discharge, the probability of malignancy is substantially higher than discharge alone.

Paget’s disease of the nipple is a distinct cancer of the nipple skin, covered in full in the next section. For a complete overview of breast cancer warning signs, see the breast cancer symptoms guide.

Paget’s Disease of the Nipple — Not Eczema

Paget’s disease of the nipple is a rare but important malignancy that accounts for approximately 1 to 3% of all breast cancers. It presents on the skin surface as an eczema-like rash of the nipple and areola, making it easy to overlook or misdiagnose as a benign skin condition — sometimes for months before the correct diagnosis is made.

Key distinction: Paget’s disease vs. nipple eczema

Benign nipple eczema is typically bilateral, improves promptly with topical corticosteroids, and is often associated with eczema elsewhere on the body. Paget’s disease is almost always unilateral, does not respond to steroid creams, and is associated with underlying breast malignancy. Any unilateral nipple rash that does not resolve with one course of topical steroid treatment must be biopsied.

Paget’s disease typically presents as redness, scaling, crusting, itching, or ulceration of the nipple and areola. There may be a serous or bloody nipple discharge. The nipple may flatten or retract as the disease progresses. It is virtually always associated with underlying breast cancer: approximately 50% of cases with a palpable mass have underlying invasive carcinoma; approximately 50% without a palpable mass have underlying DCIS.

Diagnosis is confirmed by punch biopsy or scrape cytology of the nipple, which reveals characteristic Paget cells — large malignant cells with clear cytoplasm. Mammogram and breast MRI are performed to assess the extent of underlying breast involvement before surgical planning.

Treatment depends on the underlying disease: mastectomy is traditionally required when there is an invasive mass; breast-conserving surgery with excision of the nipple-areola complex and radiation may be appropriate for DCIS without a mass in selected patients. For a complete overview of breast cancer types, stages, and treatment options, see the breast cancer overview.

The Diagnostic Process for Nipple Discharge

The evaluation of nipple discharge follows a structured stepwise approach, from clinical history through to tissue diagnosis where needed.

01 Clinical History and Examination Which breast? Which duct? Spontaneous or expressible? Color, duration, medications, recent pregnancy. Clinician inspects nipple/areola for Paget’s changes; palpates for subareolar mass; identifies the discharging duct by gentle periareolar palpation.

02 Hemoccult Test A drop of discharge is applied to a guaiac card at the bedside. A positive result indicates occult blood in the discharge and significantly elevates clinical suspicion. Negative result alone is insufficient to close a workup for suspicious discharge.

03 Breast Imaging Mammogram (standard for women ≥40): assesses calcifications, ductal changes, mass. Ultrasound: evaluates subareolar ducts, identifies intraductal lesions. MRI: recommended when mammogram and ultrasound are negative but discharge persists and remains suspicious.

04 Galactogram (Ductogram) Contrast dye injected into the discharging duct under fluoroscopy to identify filling defects (papillomas) and map the involved duct before surgery. Less commonly used now that MRI sensitivity has improved, but useful for pre-surgical duct localization.

05 Cytology Discharge applied to glass slides for cell analysis. Sensitivity for cancer is only ~20–30% — a negative result does not exclude malignancy. Positive cytology is useful confirmation but cannot be the sole basis for excluding cancer.

06 Duct Excision (Microductectomy) Surgical removal of the involved duct(s) under local or general anesthesia. Provides definitive tissue for histopathological diagnosis and simultaneously removes the source of discharge. Recommended when discharge is persistent, suspicious, and imaging is non-diagnostic.

Nipple Discharge During Pregnancy and Breastfeeding

Nipple discharge is common and expected during pregnancy and breastfeeding. Colostrum — thick yellow pre-milk — can appear as early as the second trimester. This discharge is bilateral, milky, and entirely physiological. The concern during pregnancy and breastfeeding is recognizing the rare case of pathological discharge alongside normal lactation changes.

Seek prompt evaluation during pregnancy or breastfeeding if:

Discharge is unilateral and bloody (not milk)
A new discrete mass is present in one breast
Nipple or areola skin shows persistent unilateral eczema-like changes
Mastitis is not responding to antibiotics within 7 to 10 days (inflammatory breast cancer can mimic lactation mastitis)

Ultrasound is the imaging modality of choice during pregnancy (no radiation). Mammography is safe with appropriate abdominal shielding. Core needle biopsy can be safely performed during both pregnancy and breastfeeding when a suspicious finding is present. For guidance on regular breast imaging after pregnancy, see the breast cancer screening guide.

Frequently Asked Questions

Is bloody nipple discharge always cancer?

No. The most common cause of bloody nipple discharge is intraductal papilloma — a completely benign tumor growing within a duct. Cancer is identified in approximately 5 to 12% of women presenting with nipple discharge alone, and in approximately 25 to 30% when bloody discharge accompanies a palpable mass. Bloody discharge must be evaluated promptly, but it is not synonymous with cancer.

What does it mean if my nipple discharge is clear?

Clear or watery discharge warrants evaluation because it can occasionally be associated with DCIS. A hemoccult test should be performed to check for occult blood — a positive result significantly increases concern. The workup proceeds the same way as for any suspicious discharge: clinical examination, breast imaging, and in some cases duct excision. Clear discharge that is bilateral, expressible, and occurs alongside milky discharge is more likely to represent physiological variation.

Do I need a biopsy for nipple discharge?

Not always. If evaluation finds a clearly benign cause — bilateral milky discharge with confirmed elevated prolactin, or duct ectasia with characteristic imaging — no biopsy is needed. If imaging identifies a suspicious mass or intraductal lesion, image-guided biopsy is performed. If discharge is persistent and suspicious but imaging is negative, surgical duct excision is often recommended because cytology alone cannot exclude cancer. For more detail on what breast evaluation involves, see the breast lump evaluation guide.

Can nipple discharge come and go?

Yes. Benign discharge from fibrocystic change, intraductal papilloma, or duct ectasia can fluctuate — more noticeable at certain points in the menstrual cycle, or intermittently absent and then returning. Papilloma-related discharge may vary as the lesion shifts position within the duct. The intermittent nature does not make discharge less significant. If it recurs, it should be evaluated; do not delay on the assumption that it is resolving on its own.

Can men get nipple discharge?

Yes, though far less commonly. Causes in men include gynecomastia, medications (antipsychotics, anabolic steroids, digoxin), prolactinoma, and very rarely breast cancer. Male breast cancer is rare but does occur — approximately 1% of all breast cancers affect men. Any subareolar mass in a man with nipple discharge should be clinically evaluated and biopsied if the finding is suspicious on imaging.

Dixon JM, Bundred NJ — Management of nipple discharge; World J Surg 2006
Morrogh M et al. — MRI identifies the cause of nipple discharge in women age >30; Ann Surg 2007
American Cancer Society — Paget’s disease of the breast
National Cancer Institute — Paget disease of the breast
ACR Appropriateness Criteria — Nipple discharge (2021 update)
Sabel MS — Nipple discharge (UpToDate)

This article is for educational purposes only and does not constitute medical advice. Any new or unusual nipple discharge should be evaluated by a qualified healthcare provider. Do not use this information to delay seeking clinical evaluation.

Breast Cancer Treatment: Key Advances and Approaches

Breast cancer treatment has become increasingly personalized over the past two decades, driven by advances in tumor biology characterization that distinguish meaningfully different breast cancer subtypes with different biological behaviors and optimal treatment approaches. The four major molecular subtypes of breast cancer — Luminal A (hormone receptor-positive, HER2-negative, low-grade), Luminal B (hormone receptor-positive, HER2-negative, high-grade or HER2-positive), HER2-enriched (HER2-positive, hormone receptor-negative), and triple-negative (estrogen receptor-negative, progesterone receptor-negative, HER2-negative) — each have distinct prognoses, responses to systemic therapy, and optimal treatment sequencing.

Hormone receptor-positive (HR+) breast cancer: HR+ breast cancer, which accounts for approximately 70% of cases, is treated with endocrine therapy (hormone-blocking treatment) as the cornerstone of systemic therapy. For premenopausal women, tamoxifen (5–10 years) or ovarian suppression plus an aromatase inhibitor is standard. For postmenopausal women, aromatase inhibitors (anastrozole, letrozole, exemestane) have superseded tamoxifen as the preferred endocrine therapy due to superior efficacy. In metastatic HR+ breast cancer, the CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) combined with an aromatase inhibitor or fulvestrant have transformed outcomes: the MONARCH, PALOMA, and MONALEESA trials established this combination as first-line standard of care, substantially improving progression-free and overall survival compared to endocrine therapy alone.

HER2-positive breast cancer: HER2-positive breast cancer, which accounts for approximately 15–20% of cases, was once associated with a poor prognosis but is now one of the most treatable breast cancer subtypes due to the development of HER2-targeted therapies. Trastuzumab (Herceptin) was the first anti-HER2 agent and remains a cornerstone of treatment. For early-stage HER2-positive breast cancer, neoadjuvant pertuzumab + trastuzumab + chemotherapy followed by adjuvant T-DM1 (if residual disease) is standard, based on the APHINITY and KATHERINE trials. In metastatic HER2-positive disease, trastuzumab deruxtecan (T-DXd / Enhertu) has demonstrated remarkable efficacy even in patients who have progressed through multiple prior lines of HER2-directed therapy, with response rates exceeding 60% in heavily pretreated patients (DESTINY-Breast01/02/03 trials).

Triple-negative breast cancer (TNBC): TNBC — which accounts for approximately 10–15% of breast cancers and is disproportionately common in younger women and Black women — was historically treated with cytotoxic chemotherapy alone. Several advances have improved outcomes: pembrolizumab (Keytruda) added to neoadjuvant chemotherapy for early-stage, high-risk TNBC improved event-free survival in the KEYNOTE-522 trial and is now standard for eligible patients. Olaparib (for BRCA1/2 germline mutation carriers) and sacituzumab govitecan (Trodelvy, an antibody-drug conjugate targeting Trop-2) have improved outcomes in metastatic TNBC.

For authoritative information on breast cancer, the American Cancer Society’s breast cancer resource provides patient-friendly comprehensive guides. The National Cancer Institute’s breast cancer PDQ offers evidence-based clinical summaries. The NCCN Breast Cancer Guidelines are the most widely used clinical practice standards among U.S. oncologists. For information about breast cancer symptoms that often lead to initial evaluation, see our guide to breast cancer symptoms. For information about recommended breast cancer screening approaches — including mammography and supplemental MRI for high-risk women — see our comprehensive guide to breast cancer screening. For information about what a breast lump means and how it is evaluated, see our article on breast lumps.

Breast cancer prognosis has improved substantially over the past four decades: the five-year relative survival rate for all stages combined was approximately 75% in the mid-1970s and exceeds 90% today, driven by advances in early detection through mammography screening and improvements in systemic therapy. For localized breast cancer (confined to the breast, Stage I and II), the five-year relative survival exceeds 99%. Prompt evaluation of symptoms, adherence to recommended screening intervals, and access to multidisciplinary oncology care at a breast cancer program with expertise in genomic testing and clinical trials are the most important individual-level factors in breast cancer outcomes.

Nipple Discharge: When Is It a Sign of Cancer?